News and Trends 6 Jun 2023 Head and neck cancer data presented at ASCO 2023 Results from promising trials in the fight against head and neck cancer have been presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a provider of IT, network and AI technologies, announced new […] June 6, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 1 Feb 2023 Cancer: what are the barriers to research? Everyone imagines a world without cancer, but getting there is difficult. With World Cancer Day coming up on February 4, we took the opportunity to ask some life science company CEOs, CMOs, and chief scientific officers the same question about cancer research. We asked CellCentric CEO, Will West; iOnctura CEO, Catherine Pickering; ISA Pharmaceuticals chief […] February 1, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 1 Feb 2023 How can cancer care be improved? Labiotech recently asked several biotech experts the same question about tackling cancer, for a special newsletter to commemorate World Cancer Day on February 4. The 2023 theme is Close the Care Gap. The question, what are the biggest opportunities to improve cancer care, brought responses from Versameb CEO, Klaas Zuideveld; ImaginAb CEO, Ian Wilson; ISA […] February 1, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2022 Trial for HPV16 positive oropharyngeal cancer completes enrolment for phase 2 Netherlands-based ISA Pharmaceuticals B.V., has announced that it has completed enrolment in its phase 2 clinical trial. Named OpcemISA. The trial aims to checkpoint inhibitor therapy in patients with metastatic/advanced 1st and 2nd line HPV16 positive oropharyngeal cancer (OPC). The clinical stage biotech company is developing immunotherapies to treat cancers and infectious diseases, and has […] December 1, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 8 Nov 2022 ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase 1 clinical study published. The study, using ISA Pharmaceuticals’ Amplivant adjuvant and synthetic long peptide (SLP) therapeutic vaccine technology was published by Leiden University Medical Centre (LUMC) in the Journal for ImmunoTherapy for Cancer. It […] November 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Dec 2017 Dutch and US Biotechs Team Up Against HPV-related Cancer ISA Pharmaceuticals will work together with Regeneron to combine its immunotherapy against cancer induced by HPV infection with its partner’s PD-1 checkpoint inhibitor. The human papillomavirus (HPV) is known for its ability to cause cancer, including cervical and head and neck cancer. Based in Leiden, the Netherlands, ISA Pharmaceuticals’ target choice is type 16 HPV, which […] December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Feb 2017 Stroopwaffels, Krokets and Biotechs – Meet the Top 10 in Leiden! Known for its charming canals and tulip fields, Leiden is a major tourist attraction in the Netherlands. It is also home to the oldest Dutch university and harbours the leading biotech cluster in the country. Let’s have a look at the top 10 biotechs in Leiden! Not only is Leiden the birthplace of the famous painter Rembrandt, but it […] February 28, 2017 - 7 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 7 European Institutions in the Largest Cancer Bioinformatics Collaboration Europe’s best companies using bioinformatics to tackle cancer will take part in a huge collaboration aimed at developing personalized cancer vaccines. Three biotech companies and four research institutions from Europe are taking part in the Tumor Neoantigen Selection Alliance (TESLA). This is one of the biggest oncology collaborations ever, consisting of 30 organizations and led by […] December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2016 Debunking the Immuno-Oncology Hype: is it as good as it sounds? CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype. Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitions, deals and partnerships. It seems […] September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email